Climb Bio Total Liabilities 2021-2024 | CLYM

Climb Bio total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Climb Bio Total Liabilities 2021-2024 | CLYM

Climb Bio total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.4B
Vertex Pharmaceuticals (VRTX)$125.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$106.8B
Gilead Sciences (GILD)$105.9B
CSL (CSLLY)$97.5B
GSK (GSK)$81.1B
Alnylam Pharmaceuticals (ALNY)$36.4B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.6B
Biogen (BIIB)$27.9B
Illumina (ILMN)$23.7B
Moderna (MRNA)$22.2B
BeiGene (BGNE)$22.1B
Genmab (GMAB)$15.7B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$13.1B
Insmed (INSM)$12.9B
Vaxcyte (PCVX)$12.6B
Incyte (INCY)$12.6B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.7B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.8B
Revolution Medicines (RVMD)$8.2B
Repligen (RGEN)$8B
Intra-Cellular Therapies (ITCI)$7.8B
Ascendis Pharma (ASND)$7.8B